Lineage Cell Therapeutics Inc (LCTX) - Financial and Strategic SWOT Analysis Review

Lineage Cell Therapeutics Inc (LCTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Lineage Cell Therapeutics Inc (Lineage) formerly known as BioTime Inc, is a clinical-stage biotechnology company that develops new cell therapies for unmet medical needs. It develops products based on its core proprietary technology cell-based therapy platform. The company focuses on developing new cellular therapies for neurological conditions associated with demyelination and degenerative retinal diseases. The company lead product Renevia is developed for the treatment of facial lipoatrophy and HIV lipoatrophy. Its pipeline products include OpRegen for advanced dry age-related macular degeneration, Opc1 in acute spinal cord injury, and Vac2 for non-small cell lung cancer. The company has subsidiaries in Israel, Singapore and the US. Lineage is headquartered in Carlsbad, California, the US.

Lineage Cell Therapeutics Inc Key Recent Developments

May 19,2020: Lineage Cell Therapeutics to participate in Maxim Group and M-Vest COVID-19 Virtual Conference Series on May 27, 2020
May 07,2020: Lineage Cell Therapeutics reports first quarter 2020 financial results and provides business update
Mar 12,2020: Lineage Cell Therapeutics reports fourth quarter and full year 2019 financial results and provides business update
Jan 02,2020: Lineage Cell Therapeutics conducts sale of shares in oncocyte
Dec 10,2019: Lineage Cell Therapeutics and AgeX Therapeutics announce issuance of U.S. patent for method of generating induced pluripotent stem cells

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company




Section 1 - About the Company
Lineage Cell Therapeutics Inc - Key Facts
Lineage Cell Therapeutics Inc - Key Employees
Lineage Cell Therapeutics Inc - Key Employee Biographies
Lineage Cell Therapeutics Inc - Major Products and Services
Lineage Cell Therapeutics Inc - History
Lineage Cell Therapeutics Inc - Company Statement
Lineage Cell Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
Lineage Cell Therapeutics Inc - Business Description
Product Category: Grant revenue
Performance
Product Category: Royalties from product sales and license fees
Performance
Product Category: Sale of research products and services
Performance
Product Category: Subscription and advertisement revenues
Performance
Geographical Segment: Foreign
Performance
Geographical Segment: United States
Performance
R&D Overview
Lineage Cell Therapeutics Inc - Corporate Strategy
Lineage Cell Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Lineage Cell Therapeutics Inc - Strengths
Lineage Cell Therapeutics Inc - Weaknesses
Lineage Cell Therapeutics Inc - Opportunities
Lineage Cell Therapeutics Inc - Threats
Lineage Cell Therapeutics Inc - Key Competitors
Section 3 Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 Companys Lifesciences Financial Deals and Alliances
Lineage Cell Therapeutics Inc, Medical Equipment, Deals By Year, 2014 to YTD 2020
Lineage Cell Therapeutics Inc, Medical Equipment, Deals By Type, 2014 to YTD 2020
Lineage Cell Therapeutics Inc, Recent Deals Summary
Section 5 Companys Recent Developments
May 19, 2020: Lineage Cell Therapeutics to participate in Maxim Group and M-Vest COVID-19 Virtual Conference Series on May 27, 2020
May 07, 2020: Lineage Cell Therapeutics reports first quarter 2020 financial results and provides business update
Mar 12, 2020: Lineage Cell Therapeutics reports fourth quarter and full year 2019 financial results and provides business update
Jan 02, 2020: Lineage Cell Therapeutics conducts sale of shares in oncocyte
Dec 10, 2019: Lineage Cell Therapeutics and AgeX Therapeutics announce issuance of U.S. patent for method of generating induced pluripotent stem cells
Dec 10, 2019: AgeX Therapeutics and Lineage Cell Therapeutics announce issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells
Nov 12, 2019: Lineage Cell Therapeutics reports third quarter 2019 financial results and provides business update
Oct 28, 2019: Lineage Cell Therapeutics to host therapeutic area experts at Solebury Trout Investor Event on November 15, 2019
Oct 23, 2019: Lineage Cell Therapeutics presents encouraging data on vision restoration program at Society for Neurosciences 49th Annual Scientific Meeting
Oct 07, 2019: Lineage Cell Therapeutics to chair session and present data on Vision Restoration Program at Society for Neurosciences 49th Annual Scientific Meeting on October 23, 2019
Section 6 Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables


Lineage Cell Therapeutics Inc, Key Facts
Lineage Cell Therapeutics Inc, Key Employees
Lineage Cell Therapeutics Inc, Key Employee Biographies
Lineage Cell Therapeutics Inc, Major Products and Services
Lineage Cell Therapeutics Inc, History
Lineage Cell Therapeutics Inc, Subsidiaries
Lineage Cell Therapeutics Inc, Key Competitors
Lineage Cell Therapeutics Inc, Ratios based on current share price
Lineage Cell Therapeutics Inc, Annual Ratios
Lineage Cell Therapeutics Inc, Annual Ratios (Cont...1)
Lineage Cell Therapeutics Inc, Annual Ratios (Cont...2)
Lineage Cell Therapeutics Inc, Interim Ratios
Lineage Cell Therapeutics Inc, Medical Equipment, Deals By Year, 2014 to YTD 2020
Lineage Cell Therapeutics Inc, Medical Equipment, Deals By Type, 2014 to YTD 2020
Lineage Cell Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures


Lineage Cell Therapeutics Inc, Performance Chart (2015 - 2019)
Lineage Cell Therapeutics Inc, Ratio Charts
Lineage Cell Therapeutics Inc, Medical Equipment, Deals By Year, 2014 to YTD 2020
Lineage Cell Therapeutics Inc, Medical Equipment, Deals by Type, 2014 to YTD 2020

Lineage Cell Therapeutics Inc (LCTX) - Financial and Strategic SWOT Analysis Review

Lineage Cell Therapeutics Inc (LCTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled

USD 125 View Report

Asia Pacific Natural Killer (NK) Cell Therapeutics Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Asia Pacific Natural Killer (NK) Cell Therapeutics market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX

USD 3000 View Report

Europe Natural Killer (NK) Cell Therapeutics Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Europe Natural Killer (NK) Cell Therapeutics market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million

USD 3000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available